László Rovó

László Rovó

Auto-generated profile, based on publicly available information

László Rovó

Department of Oto-Rhino-Laryngology and Head-Neck Surgery, University of Szeged, Szeged, Hungary

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2025 in Drug Delivery
Verified
Journal Article
Open access
MSMaryana Salamah
Maryana Salamah
Bence SiposBence Sipos
Bence Sipos
Zsuzsanna SchelzZsuzsanna Schelz
Zsuzsanna Schelz
IZIstvan Zupko
Istvan Zupko
ÁKÁgnes Kiricsi
Ágnes Kiricsi
Ildikó CsókaIldikó Csóka
Ildikó Csóka
The present study aimed to prepare and optimize lamotrigine-loaded bovine serum albumin nanoparticles (LAM-NP) using the Quality by Design (QbD) approach and to investigate both the in vitro and ex vivo effects of different cross-linking agents glutaraldehyde (GLUT), glucose (GLUC) and 1-(3-dimethylaminutesopropyl)-3-ethylcarbodiimide hydrochloride (EDC) on intranasal applicability. Cross-linked LAM-NP from EDC (NP-EDC-1) showed the lowest Z-average value (163.7 ± 1.9 nm) and drug encapsulation efficacy (EE%) of 97.31 ± 0.17%. The drug release of GLUC cross-linked LAM-NP (NP-GLUC-9), glutaraldehyde cross-linked LAM-NP (NP-GLUT-2), and NP-EDC-1 at blood circulation conditions was higher than the initial LAM. The results of the blood-brain barrier parallel artificial membrane permeability assay (BBB-PAMPA) showed an increase in the permeability of LAM through the BBB with NP-GLUC-9 and an increase in flux with all selected formulations. The ex vivo study showed that LAM diffusion from the selected formulations through the human nasal mucosa was higher than in case of initial LAM. The cytotoxicity study indicated that BSA-NP reduced LAM toxicity, and GLUC 9 mM and EDC 1 mg could be alternative cross-linking agents to avoid GLUT 2% v/v toxicity. Furthermore, permeability through Caco-2 cells showed that nasal epithelial transport/absorption of LAM was improved by using BSA-NPs. The use of BSA-NP may be a promising approach to enhance the solubility, permeability through BBB and decrease the frequency of dosing and adverse effects of LAM.

2 December 2021 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
LRLászló Rovó
László Rovó
VMVera Matievics
Vera Matievics
BSBalázs Sztanó
Balázs Sztanó
LSLászló Szakács
László Szakács
DPDóra Pálinkó
Dóra Pálinkó
ÁBÁdám Bach
Ádám Bach
Purpose: Endoscopic arytenoid abduction lateropexy (EAAL) is a reliable surgical solution for the minimally invasive treatment of bilateral vocal fold palsy (BVFP), providing a stable airway by the lateralization of the arytenoid cartilages with a simple suture. The nondestructive manner of the intervention theoretically leads to higher regeneration potential, thus better voice quality. The study aimed to investigate the respiratory and phonatory outcomes of this treatment concept. Methods: 61 BVFP patients with significant dyspnea associated with thyroid/parathyroid surgery were treated by unilateral EAAL. Jitter, Shimmer, Harmonics to Noise Ratio, Maximum Phonation Time, Fundamental frequency, Voice Handicap Index, Dysphonia Severity Index, Friedrich’s Dysphonia Index, Global-Roughness-Breathiness scale, Quality of Life, and Peak Inspiratory Flow were evaluated 18 months after EAAL. Results: All patients had a stable and adequate airway during the follow-up. Ten patients (16.4%) experienced complete bilateral motion recovery with objective acoustic parameters in the physiological ranges. Most functional results of the 13 patients (21.3%) with unilateral recovery also reached the normal values. Fifteen patients (24.6%) had unilateral adduction recovery only, with slightly impaired voice quality. Eleven patients (18.0%) had false vocal fold phonation with socially acceptable voice. In 12 patients (19.7%) no significant motion recovery was detected on the glottic level. Conclusion: EAAL does not interfere with the potential regeneration process and meets the most important phoniatric requirements while guaranteeing the reversibility of the procedure—therefore serving patients with transient palsy. Further, a socially acceptable voice quality and an adequate airway are ensured even in cases of permanent bilateral vocal fold paralysis.

1 May 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
MSMaryana Salamah
Maryana Salamah
Balázs VolkBalázs Volk
Balázs Volk
ILIstvan Lekli
Istvan Lekli
IBIstván Bak
István Bak
AGAlexandra Gyöngyösi
Alexandra Gyöngyösi
György Tibor BaloghGyörgy Tibor Balogh
György Tibor Balogh
Purpose: The present study aimed to develop and compare the intranasal applicability of favipiravir-loaded aspasomes (FAV-ASPs) using film hydration method, and favipiravir-loaded niosomes (FAV-NIOs) using ethanol injection method. Methods: The FAV-ASP and FAV-NIO formulations were characterized according to nanoparticulate characteristics (DLS, drug loading, drug encapsulation efficacy, droplet size distribution), drug release and permeability behavior. Results: The optimized FAV-ASP formulation (FAV-ASP8) consisted of FAV, ascorbyl palmitate, Span® 60 and cholesterol (30:25:25:50 w/w) with nano-scale size range (292.06 ± 2.10 nm), narrow polydispersity index (PDI) value (0.36 ± 0.03), adequate zeta potential (− 74.73 ± 3.28 mV) and acceptable encapsulation efficiency (55.33 ± 0.41%). The optimized FAV-NIO formulation (FAV-NIO9) contained FAV, Span® 60 and cholesterol (30:30:40 w/w) with nano-scale size range (167.13 ± 1.60 nm), narrow PDI value (0.07 ± 0.01), adequate zeta potential (− 27.1 ± 1.24 mV) and acceptable encapsulation efficiency (51.30 ± 0.69%). FAV-ASP8 and FAV-NIO9 were suitable for spraying into the nasal cavity (droplet size distribution < 200 μm). In vitro drug release and permeability studies demonstrated enhanced solubility and increased blood–brain barrier (BBB) permeability of FAV formulations, respectively. The ex vivo human nasal permeability study revealed that FAV diffusion from FAV-ASP8 was higher than from FAV-NIO9 or initial FAV. Furthermore, the in vivo animal study showed that FAV-ASP8 had a higher BBB penetration compared to FAV-NIO9 and pure FAV. The in vitro–in vivo correlation study showed good correlation between the in vitro and the in vivo pharmacokinetic data. Conclusion: FAV-ASP8 for nose-to-brain delivery system could be a promising formulation to improve FAV bioavailability compared to FAV-NIO9.

16 October 2020 in The Journal of International Advanced Otology
Verified
Journal Article
Open access
ZBZsofia Bere
Zsofia Bere
GVGabor Vass
Gabor Vass
APAdam Perenyi
Adam Perenyi
ZTZoltan Tobias
Zoltan Tobias
LRLaszlo Rovo
Laszlo Rovo
Bone-anchored hearing aids (BAHAs) have been used for multiple types of hearing loss both in pediatric and adult cases. In the last decades, the percutaneous BAHA® Connect System (Cochlear Ltd., Sydney, Australia) was replaced by the fully implanted transcutaneous, magnet-based BAHA® Attract System (Cochlear Ltd., Sydney, Australia). Since the implantable part of the Attract device is fully covered with soft tissue, skin complications that were frequently observed in the percutaneous system, could be eliminated. As an outcome of this important advantage of the Attract System, conversion of the percutaneous into a transcutaneous system should be considered. In the following methodology report, a possible surgical technique is described. The method can easily be adopted to different conditions in which the replacement of the percutaneous device is necessary. Cite this article as: Bere Z, Vass G, Perenyi A, Tobias Z, Rovo L. Surgical Solution for the Transformation of the Percutaneous Bone Anchored Hearing Aid to a Transcutaneous System in Complicated Cases. J Int Adv Otol 2020; 16(3): 476-80.

1 October 2017 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
GVGábor Vass
Gábor Vass
ZBZsolt Bella
Zsolt Bella
ZTZoltán Tóbiás
Zoltán Tóbiás
ANAttila Nagy
Attila Nagy
LILászló Iván
László Iván
LRLászló Rovó
László Rovó

27 January 2025 in Sensors
Verified
Journal Article
Open access
PDF file
ÁPÁdám Pannonhalmi
Ádám Pannonhalmi
BPBálint Posta
Bálint Posta
ÁPÁdám Perényi
Ádám Perényi
LRLászló Rovó
László Rovó
BBBalázs Bende
Balázs Bende
LSLászló Szakács
László Szakács
Telemedicine brings several benefits to patients, healthcare providers, and the wider society, including reductions in the need for hospitalizations or readmissions, as well as in overall healthcare costs and the length of inpatient stay. In addition, these services may provide psychological benefits to patients, including excellent satisfaction and medication adherence. The present study aimed to investigate an in-house-developed otorhinolaryngologic remote diagnostic system (mobile app). The basis of the comparison was the incidence between the diagnoses and therapies made by remote diagnosticians and on-site specialists based on static images and videos captured by a smartphone otoscope device. In the study, 103 patients were involved. After registering demographic data, the telemedicine software was evaluated by comparing the matching of physically established diagnoses and/or therapies with remotely established diagnoses and/or therapies. The most remarkable result was in concordance with the diagnoses, with 79 matches identified of the 103 cases examined; the rate of the matching cases was 76.7% (95% CI: 68.5–84.9%). These results support that telemedicine-based otorhinolaryngological remote diagnostics could play a significant role in future healthcare.